Cristalli G, Mills D C
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140.
Biochem J. 1993 May 1;291 ( Pt 3)(Pt 3):875-81. doi: 10.1042/bj2910875.
The synthesis of a new analogue of ADP, 2-(p-azidophenyl)-ethythioadenosine 5'-diphosphate (AzPET-ADP), is described. This compound contains a photolabile phenylazide group attached to the ADP molecule by a thioether link at the purine 2 position. It has been prepared in radioactive form with 32P in the beta-phosphate at a specific radioactivity of 100 mCi/mumol. The reagent activated platelets, causing shape change and aggregation, with somewhat lower affinity than ADP. On photolysis the affinity was increased. The reagent also inhibited platelet adenylate cyclase stimulation by prostaglandin E1, with considerably higher affinity than ADP. On photolysis the affinity was decreased. AzPET-ADP competitively inhibited the binding of 2-methylthio[beta-32P]ADP, a ligand for the receptor by which ADP causes inhibition of adenylate cyclase. In the dark, AzPET-[beta-32P]ADP bound reversibly and with high affinity to a single population of sites similar in number to the sites that bind 2-methylthio[beta-32P]ADP. Binding was inhibited by ADP and by ATP and by p-chloromercuribenzenesulphonic acid (pCMBS). On exposure to u.v. light in the presence of platelets, AzPET-[beta-32P]ADP was incorporated covalently but non-specifically into several platelet proteins, although prominent intracellular proteins were not labelled. Specific labelling was confined to a single region of SDS/polyacrylamide gels, overlying but not comigrating with actin. Incorporation of radioactivity into this region was inhibited by ADP and by ATP as well as by ADP beta S, ATP alpha S and pCMBS, but not by adenosine, GDP or AMP. Inhibition of AzPET-[beta-32P]ADP incorporation was closely correlated with inhibition of equilibrium binding of 2-methylthio[beta-32P]ADP. These results suggests that the labelled protein, which migrates with an apparent molecular mass of 43 kDa in reduced gels, is the receptor through which ADP inhibits adenylate cyclase.
本文描述了一种新的ADP类似物,即2-(对叠氮苯基)-乙硫基腺苷5'-二磷酸(AzPET-ADP)的合成。该化合物在嘌呤2位通过硫醚键连接有一个光不稳定的苯基叠氮基团。它已被制备成放射性形式,β-磷酸中的32P的比活度为100 mCi/μmol。该试剂可激活血小板,引起形态变化和聚集,其亲和力略低于ADP。光解后亲和力增加。该试剂还能抑制前列腺素E1对血小板腺苷酸环化酶的刺激,其亲和力比ADP高得多。光解后亲和力降低。AzPET-ADP竞争性抑制2-甲硫基[β-32P]ADP的结合,2-甲硫基[β-32P]ADP是ADP通过其受体抑制腺苷酸环化酶的配体。在黑暗中,AzPET-[β-32P]ADP以高亲和力可逆地结合到单一的位点群体上,其数量与结合2-甲硫基[β-32P]ADP的位点相似。ADP、ATP和对氯汞苯磺酸(pCMBS)可抑制其结合。在血小板存在的情况下,暴露于紫外光下,AzPET-[β-32P]ADP会共价但非特异性地掺入几种血小板蛋白中,尽管未标记突出的细胞内蛋白。特异性标记局限于SDS/聚丙烯酰胺凝胶的单个区域,位于肌动蛋白之上但不与之共迁移。放射性掺入该区域受到ADP、ATP以及ADPβS、ATPαS和pCMBS的抑制,但不受腺苷、GDP或AMP的抑制。AzPET-[β-32P]ADP掺入的抑制与2-甲硫基[β-32P]ADP平衡结合的抑制密切相关。这些结果表明,在还原凝胶中表观分子量为43 kDa的标记蛋白是ADP通过其抑制腺苷酸环化酶的受体。